Mycoplasma Detection

Mycoplasma detection is a critical safety test for any biopharmaceutical product produced in cell culture. Mycoplasma are a genus of small, wall-less bacteria that can silently infect cell cultures, altering cell metabolism and compromising product quality without the typical signs of bacterial contamination like turbidity. Because they are resistant to many antibiotics and can pass through standard sterilizing filters, they pose a significant risk to manufacturing. This procedure outlines the methods used to ensure that cell banks, raw materials, and the final product are free from this adventitious agent, a non-negotiable requirement for patient safety.

Legacy: The traditional compendial culture method has been the gold standard for decades. It involves inoculating samples into specialized broth and agar media and incubating for 28 days. While sensitive, it is extremely slow.

Current Standard: Nucleic Acid Amplification Techniques (NAT), specifically quantitative PCR (qPCR), have become the modern standard. These methods are rapid (providing results in hours), highly sensitive, and are accepted as alternatives to the compendial culture method once full validation and equivalence to culture have been demonstrated. Several pharmacopeias and regulatory authorities now allow NAT for routine lot release under these conditions.

Future: The field is moving towards even faster and higher-throughput NAT-based methods, including the potential use of Next-Generation Sequencing (NGS) for broad adventitious agent detection and digital PCR (dPCR) for highly precise quantification.

There are two primary methods for detecting Mycoplasma, each based on a different biological principle:

• Culture-Based Method: This method aims to grow any viable Mycoplasma present in the sample. The test sample is inoculated into a sensitive indicator cell line (like Vero cells) and also directly onto specialized, nutrient-rich agar and broth media. The cultures are incubated for 28 days under specific atmospheric conditions.
• NAT-Based Method (qPCR): This method detects the genetic material (DNA) of Mycoplasma. DNA is extracted from the test sample. This DNA is then mixed with primers and probes that are specific to highly conserved regions of the Mycoplasma genome (like the 16S rRNA gene). A qPCR instrument amplifies any Mycoplasma DNA present. The probe releases a fluorescent signal as the DNA is amplified, and the instrument detects this signal in real-time. A positive signal indicates the presence of Mycoplasma DNA.

• Culture Method: Data Output: Visual observation of agar plates and indicator cells.
• Interpretation: The presence of any characteristic "fried egg" colonies on the agar, or specific staining patterns on the indicator cells, is a positive result. The absence of any growth after 28 days is a negative result.
• qPCR Method: Data Output: An amplification plot showing fluorescence versus PCR cycle number.
• Interpretation: If the sample's fluorescence signal crosses a predefined threshold, it is considered positive. If no signal is detected after a set number of cycles, the result is negative. 

• Culture Method: Considered the historical "gold standard" as it detects only viable, growing organisms.
• qPCR Method: Speed: Extremely fast, with results in hours instead of weeks.
• High Sensitivity & Specificity: Can detect very low levels of contamination and is highly specific for Mycoplasma.
• Broad Detection: Can detect fastidious or non-culturable strains that might be missed by the culture method.

• Culture Method: Extremely Slow: The 28-day incubation time creates a major bottleneck in manufacturing timelines.
• Labor-Intensive: Requires extensive aseptic technique and manual observation.
• May Miss Viable but Non-Culturable (VBNC) strains.
• qPCR Method: Detects DNA, Not Viability: A positive result indicates the presence of Mycoplasma DNA, but it cannot distinguish between live and dead organisms. This requires careful investigation of any positive result.
• Susceptible to Inhibition: Components in the sample matrix can sometimes inhibit the PCR reaction, requiring robust DNA extraction procedures.

Validation of a NAT-based method as an alternative to the culture method is a rigorous process:

• Specificity: Must be shown to detect a broad range of Mycoplasma species and not cross-react with other related bacteria.
• Limit of Detection (LOD): The sensitivity must be demonstrated to be equivalent to or better than the culture method (typically ≤ 10 CFU/mL).
• Robustness: The method must perform consistently despite small variations in procedure.
• Equivalency: A formal study comparing the NAT method to the compendial culture method is typically required by regulators.

• Reference Materials: Certified reference materials containing a known number of inactivated Mycoplasma organisms or purified genomic DNA are used to validate and control the qPCR assay.
• Pharmacopeial Standards: The validation and execution of Mycoplasma tests must follow the procedures and standards outlined in the major pharmacopeias.

• Mycoplasma testing is a universal requirement for any product derived from eukaryotic cell culture, including:
• Monoclonal Antibodies (mAbs) & Recombinant Proteins
• Cell & Gene Therapy Products; For ATMPs (cell therapies), Mycoplasma NAT is often preferred due to extremely short shelf-life (culture impractical).
• Tissue-Engineered Products
• Vaccines (cell-based)